Craig T. Jordan

University of Colorado Anschutz Medical Campus — United States

Medicine · Health Sciences

76h-index26.8kcitations534works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(250), Histone Deacetylase Inhibitors Research(84), Protein Degradation and Inhibitors(68), Chronic Myeloid Leukemia Treatments(60), Multiple Myeloma Research and Treatments(49)

Publications534 total

Federated penalized piecewise exponential model for horizontally distributed survival data: FedPPEM
2026Open Access
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML
Cell Metabolism·2026
Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse
Leukemia·2025
Supplementary Table 7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Figures S1-S7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Table 6 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Table 1 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Tables 3-5 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Table 2 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Table 8 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Supplementary Table 9 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2025Open Access
Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine
JCO Clinical Cancer Informatics·2025Open Access
Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia
Blood·2025Open Access
Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)
Blood·2025
Targeting nicotinamide salvage pathway is a unique metabolic vulnerability of high-risk MDS stem cells
Blood·2025Open Access
A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential
Cell Reports·2025· 1 citedOpen Access
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial
EClinicalMedicine·2025Open Access
siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor Cells
2025Open Access
Repeated Dosing of Apoptotic Donor B Cell Infusions for Tolerance in a Non-Human Primate Model of Allogeneic Kidney Transplantation
American Journal of Transplantation·2025Open Access
SCUBA implements a storage format-agnostic API for single-cell data access in R
F1000Research·2025· 1 citedOpen Access
page 1 of 27Next →

Frequent Co-authors

Daniel A. Pollyea(13), Shanshan Pei(12), Brett M. Stevens(11), Mónica L. Guzmán(10), John M. Ashton(9), Michael W. Becker(8), Clayton A. Smith(8), Mohammad Minhajuddin(7), Courtney L. Jones(7), Angelo D’Alessandro(7), Amanda Winters(6), Diana Abbott(6), Haobin Ye(6), Randall M. Rossi(5), Sarah J. Neering(5), Jane L. Liesveld(5), Rachel Culp‐Hill(5), Ihor R. Lemischka(5), Nabilah Khan(5), Biniam Adane(5)